Physician profile
Angela D Harper
NPI 1801860515
$3,176.57
in general payments reported to CMS, 2019-2025
30 companies · $801 in 2025
The $801 reported for 2025 was more than what 80% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $199 · 2021: $235 · 2022: $167 · 2023: $434 · 2024: $993 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.08 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $523.50 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $274.23 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $237.47 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $210.74 | 2022-2025 | Aplenzin |
| Alkermes, INC. | $183.22 | 2020-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $153.47 | 2019-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.34 | 2023-2025 | Caplyta |
| Noven Therapeutics, LLC | $117.46 | 2024-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $95.67 | 2022-2025 | Auvelity |
| Tris Pharma INC | $64.40 | 2022-2023 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $58.59 | 2019 | |
| Almatica Pharma LLC | $57.67 | 2023-2024 | Loreev Xr |
| Corium, LLC | $54.11 | 2023-2024 | Azstarys |
| Shire North American Group INC | $46.83 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $42.10 | 2019-2025 | Fanapt, Hetlioz |
| Adlon Therapeutics L.P. | $41.53 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $39.43 | 2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $37.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.66 | 2020-2022 | |
| Biogen, INC. | $30.26 | 2024 | Vumerity |
| Teva Pharmaceuticals USA, INC. | $30.25 | 2023 | Austedo Xr, Uzedy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.61 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.98 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $14.31 | 2025 | Jornay Pm |
| Allergan, INC. | $13.99 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.97 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.19 | 2019 | |
| Neos Therapeutics, Lp | $11.71 | 2020 | |
| Eisai INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.